741 related articles for article (PubMed ID: 27908728)
21. Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis.
Russell M; Thompson F; Spier C; Taetle R
Leukemia; 1993 Oct; 7(10):1654-7. PubMed ID: 8412328
[TBL] [Abstract][Full Text] [Related]
22. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
23. Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
Abrahamsson AE; Geron I; Gotlib J; Dao KH; Barroga CF; Newton IG; Giles FJ; Durocher J; Creusot RS; Karimi M; Jones C; Zehnder JL; Keating A; Negrin RS; Weissman IL; Jamieson CH
Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3925-9. PubMed ID: 19237556
[TBL] [Abstract][Full Text] [Related]
24. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y
Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566
[TBL] [Abstract][Full Text] [Related]
25. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
Coluccia AM; Vacca A; Duñach M; Mologni L; Redaelli S; Bustos VH; Benati D; Pinna LA; Gambacorti-Passerini C
EMBO J; 2007 Mar; 26(5):1456-66. PubMed ID: 17318191
[TBL] [Abstract][Full Text] [Related]
26. [Expression of beta-Catenin Gene in CML and its relationship with bcr/abl].
Li ZJ; Qiu LG; Li X; Mai YJ; Wang GR; Yu Z; Wang YF; Li CH; Li Q
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):931-5. PubMed ID: 17956664
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
[TBL] [Abstract][Full Text] [Related]
28. Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
Nakahara F; Kitaura J; Uchida T; Nishida C; Togami K; Inoue D; Matsukawa T; Kagiyama Y; Enomoto Y; Kawabata KC; Chen-Yi L; Komeno Y; Izawa K; Oki T; Nagae G; Harada Y; Harada H; Otsu M; Aburatani H; Heissig B; Hattori K; Kitamura T
Blood; 2014 Jun; 123(25):3932-42. PubMed ID: 24825862
[TBL] [Abstract][Full Text] [Related]
29. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
30. Enhanced expression of p210BCR/ABL and aberrant expression of Zfp423/ZNF423 induce blast crisis of chronic myelogenous leukemia.
Miyazaki K; Yamasaki N; Oda H; Kuwata T; Kanno Y; Miyazaki M; Komeno Y; Kitaura J; Honda Z; Warming S; Jenkins NA; Copeland NG; Kitamura T; Nakamura T; Honda H
Blood; 2009 May; 113(19):4702-10. PubMed ID: 19234145
[TBL] [Abstract][Full Text] [Related]
31. Morphine activates blast-phase chronic myeloid leukemia cells and alleviates the effects of tyrosine kinase inhibitors.
Zhou Z; Liu T; Zhang J
Biochem Biophys Res Commun; 2019 Dec; 520(3):560-565. PubMed ID: 31615652
[TBL] [Abstract][Full Text] [Related]
32. Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis.
Ashur-Fabian O; Adamsky K; Trakhtenbrot L; Cohen Y; Raanani P; Hardan I; Nagler A; Rechavi G; Amariglio N
Cell Cycle; 2007 Mar; 6(5):589-94. PubMed ID: 17361096
[TBL] [Abstract][Full Text] [Related]
33. Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia.
Karabay AZ; Koc A; Ozkan T; Hekmatshoar Y; Altinok Gunes B; Sunguroglu A; Buyukbingol Z; Atalay A; Aktan F
Hematology; 2018 Dec; 23(10):765-770. PubMed ID: 29945498
[TBL] [Abstract][Full Text] [Related]
34. Biphenotypic blast crisis of chronic myelogenous leukemia: abnormalities of p53 and retinoblastoma genes.
Ishikura H; Yufu Y; Yamashita S; Abe Y; Okamura T; Motomura S; Nishimura J; Nawata H
Leuk Lymphoma; 1997 May; 25(5-6):573-8. PubMed ID: 9250829
[TBL] [Abstract][Full Text] [Related]
35. Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26).
Suzukawa K; Taki T; Abe T; Asoh H; Kamada N; Yokota J; Morishita K
Genomics; 1997 Jun; 42(2):356-60. PubMed ID: 9192861
[TBL] [Abstract][Full Text] [Related]
36. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
[TBL] [Abstract][Full Text] [Related]
37. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
[TBL] [Abstract][Full Text] [Related]
38. EVI1 targets platelet endothelial cell adhesion molecule and up-regulates its expression in chronic myeloid leukemia.
Pradhan AK; Chakraborty S
Leuk Lymphoma; 2014 Apr; 55(4):954-6. PubMed ID: 23772643
[No Abstract] [Full Text] [Related]
39. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
[TBL] [Abstract][Full Text] [Related]
40. Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Mukherjee K; Sha X; Magimaidas A; Maifrede S; Skorski T; Bhatia R; Hoffman B; Liebermann DA
Oncotarget; 2017 Feb; 8(7):10809-10821. PubMed ID: 28086219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]